Literature DB >> 25179796

Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function.

Marie-Laure Persechini1, Isabelle Gennero, Solange Grunenwald, Delphine Vezzosi, Antoine Bennet, Philippe Caron.   

Abstract

INTRODUCTION: A decrease of insulin-like growth factor-I levels (IGF-I) has been reported during the first trimester of pregnancy in women with acromegaly before the secretion of placental growth hormone (GH) progressively increases IGF-1 concentration. STUDY
DESIGN: To evaluate variations of concentrations of IGF-1, insulin-like growth factor (IGF)-binding protein-3 (IGF-BP3) and GH during the first trimester of pregnancy in women with normal somatotroph function. PATIENTS AND METHODS: Sixteen women (median age 31 years) with as who were followed for benign thyroid disorders (n = 15) or prolactin-secreting microadenoma (n = 1) were evaluated before and in the first trimester of pregnancy. Serum concentrations of GH, IGF-1, IGF-BP3, TSH and estradiol (E2) were measured before and in the first trimester (5.4 ± 2.2 weeks of gestation).
RESULTS: Before pregnancy, somatotroph and thyroid functions (median TSH 1.2 mU/L) were normal in all women. At the first trimester IGF-1 levels decreased significantly (before = 210 ng/mL, first trimester = 145 ng/mL, p < 0.001) with no significant change in GH (before = 1.5 ng/mL, first trimester = 0.84 ng/mL) or IGF-BP3 levels (before = 2.3 ng/mL, first trimester = 2.2 ng/mL), while estradiol levels increased significantly (before = 46.5 pg/100 mL, first trimester = 448.5 pg/100 mL, p < 0.001).
CONCLUSION: In women with normal somatotroph function, IGF-1 levels decrease in the first trimester of pregnancy without changes in GH or IGF-BP3 levels. These results confirm liver resistance to GH as a consequence of the physiological increase of estrogens during the first trimester.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25179796     DOI: 10.1007/s11102-014-0596-3

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  27 in total

1.  Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity.

Authors:  L C Giudice; E M Farrell; H Pham; G Lamson; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

2.  Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women.

Authors:  P Ovesen; N Vahl; S Fisker; J D Veldhuis; J S Christiansen; J O Jørgensen
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

3.  Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study.

Authors:  S I Helle; I H Omsjø; S C Hughes; L Botta; G Hüls; J M Holly; P E Lønning
Journal:  Clin Endocrinol (Oxf)       Date:  1996-12       Impact factor: 3.478

4.  Placental and pituitary growth hormone secretion during pregnancy in acromegalic women.

Authors:  A Beckers; A Stevenaert; J M Foidart; G Hennen; F Frankenne
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

5.  Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.

Authors:  Philippe Caron; Stéphanie Broussaud; Jérome Bertherat; Françoise Borson-Chazot; Thierry Brue; Christine Cortet-Rudelli; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

Review 6.  Human placenta as an endocrine organ.

Authors:  Danièle Evain-Brion; André Malassine
Journal:  Growth Horm IGF Res       Date:  2003-08       Impact factor: 2.372

7.  Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.

Authors:  Emmanuel Sonnet; Karine Lacut; Nathalie Roudaut; Dominique Mottier; Véronique Kerlan; Emmanuel Oger
Journal:  Clin Endocrinol (Oxf)       Date:  2007-05       Impact factor: 3.478

Review 8.  Estrogen regulation of growth hormone action.

Authors:  Kin-Chuen Leung; Gudmundur Johannsson; Gary M Leong; Ken K Y Ho
Journal:  Endocr Rev       Date:  2004-10       Impact factor: 19.871

9.  Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp.

Authors:  Susan B Hudson; Darrell R Schroeder; Joy N Bailey; Kristi L Mielke; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2009-10-26       Impact factor: 5.958

10.  Somatomedins in pregnancy: a cross-sectional study of insulin-like growth factors I and II and somatomedin peptide content in normal human pregnancies.

Authors:  D M Wilson; A Bennett; G D Adamson; R J Nagashima; F Liu; M L DeNatale; R L Hintz; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1982-11       Impact factor: 5.958

View more
  4 in total

1.  Early pregnancy IGF-I and placental GH and risk of epithelial ovarian cancer: A nested case-control study.

Authors:  Helena Schock; Renée T Fortner; Heljä-Marja Surcel; Kjell Grankvist; Eero Pukkala; Matti Lehtinen; Eva Lundin
Journal:  Int J Cancer       Date:  2014-12-17       Impact factor: 7.396

2.  Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients' Perspective.

Authors:  Andrew R Hoffman; Tracy Mathison; Deno Andrews; Kristine Murray; Nicky Kelepouris; Maria Fleseriu
Journal:  J Endocr Soc       Date:  2022-05-12

Review 3.  Gender in Endocrine Diseases: Role of Sex Gonadal Hormones.

Authors:  R Lauretta; M Sansone; A Sansone; F Romanelli; M Appetecchia
Journal:  Int J Endocrinol       Date:  2018-10-21       Impact factor: 3.257

Review 4.  Pregnancy and acromegaly.

Authors:  Ammar Muhammad; Sebastian J Neggers; Aart J van der Lely
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.